(Q33949871)

30 July 2017

Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy (English)

1 reference

30 July 2017

1 reference

6

Ingrid U Scott

1 reference

30 July 2017

José A R Filho

1

1 reference

30 July 2017

André Messias

2

1 reference

30 July 2017

Felipe P P Almeida

3

1 reference

30 July 2017

Jefferson A S Ribeiro

4

1 reference

30 July 2017

Rogério A Costa

5

1 reference

30 July 2017

Rodrigo Jorge

7

1 reference

30 July 2017

5 July 2011

1 reference

30 July 2017

1 reference

30 July 2017

89

1 reference

30 July 2017

7

1 reference

30 July 2017

e567-72

1 reference

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

30 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Pharmacokinetics of intravitreal ranibizumab (Lucentis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Subclinical diabetic macular edema and mild non-proliferative diabetic retinopathy: data correlation with the retinal thickness analyzer (RTA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02184.X

10.1111/J.1755-3768.2011.02184.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference